Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Mirati Therapeutics doses first patient in MRTX849 trial

Micrograph showing a PD-L1 positive non-small cell lung carcinoma. Credit: Nephron.

  • Mirati Therapeutics

Go Top